Clinical Trials

Preclinical data demonstrate potential of prodrug technology

Published in Gene Therapy Weekly, December 15th, 2005

Semafore Pharmaceuticals, Inc., an emerging leader in small molecule cancer therapies addressing critical cell signaling pathways, presented new data that add to the growing body of preclinical data demonstrating the clinical potential of Semafore's proprietary targeted prodrug technology.

The data also support the safety and potential efficacy of its lead targeted PI3K kinase inhibitor SF1126 as a new approach to treating cancer, as well as the company's plans to advance SF1126 into clinical trials in 2006. The data were presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry